Lymphangioleiomyomatosis

Cancer Control

Volumn 13, Issue 4, 2006, Pages 276-285

  Taveira DaSilva, Angelo M ^a   Steagall, Wendy K ^a   Moss, Joel ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; CARBON MONOXIDE; ESTROGEN; GONADORELIN; MATRIX METALLOPROTEINASE INHIBITOR; RAPAMYCIN;

ABDOMINAL BLEEDING; CANCER DIAGNOSIS; CANCER GROWTH; CHYLOTHORAX; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; EXERCISE; FORCED EXPIRATORY VOLUME; HORMONAL THERAPY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG DIFFUSION CAPACITY; LUNG FUNCTION TEST; LYMPHANGIOLEIOMYOMATOSIS; MORBIDITY; MORTALITY; OXYGEN THERAPY; PATHOPHYSIOLOGY; PNEUMOTHORAX; PREVALENCE; REVIEW;

EID: 33750157185     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327480601300405     Document Type: Review

References (105)

1. Kitaichi M, Nishimura K, Itoh H, et al. Pulmonary lymphangiomyomatosis: a report of 46 patients including a clinicopathologic study of prognostic factors. Am J Respir Crit Care Med. 1995;151:527-533.
2. Urban T, Lazor R, Lacronique J, et al. Pulmonary lymphangioleiomyomatosis: a study of 69 patients. Groupe d'Etudes et de Recherche sur les Maladies "Orphelines" Pulmonaires (GERM"O"P). Medicine (Baltimore). 1999;78:321-337.
3. Chu SC, Horiba K, Usuki J, et al. Comprehensive evaluation of 35 patients with lymphangioleiomyomatosis. Chest. 1999;115:1041-1052.
4. Johnson SR, Tattersfield AE. Clinical experience of lymphangioleiomyomatosis in the UK. Thorax. 2000;55:1052-1057.
5. Ryu JH, Moss J, Beck GJ, et al. The NHLBI Lymphangioleiomyomatosis Registry: characteristics of 230 patients at enrollment. Am J Respir Crit Care Med. 2006;173:105-111. Epub 2005 Oct 6.
6. Costello LC, Hartman TE, Ryu JH. High frequency of pulmonary lymphangioleiomyomatosis in women with tuberous sclerosis complex. Mayo Clin Proc. 2000;75:591-594.
7. Moss J, Avila NA, Barnes PM, et al. Prevalence and clinical characteristics of lymphangioleiomyomatosis (LAM) in patients with tuberous sclerosis complex. Am J Respir Crit Care Med. 2001;164:669-671.
8. Franz DN, Brody A, Meyer C, et al. Mutational and radiographic analysis of pulmonary disease consistent with lymphangioleiomyomatosis and micronodular pneumocyte hyperplasia in women with tuberous sclerosis. Am J Respir Crit Care Med. 2001;164:661-668.
9. Osborne JP, Fryer A, Webb D. Epidemiology of tuberous sclerosis. Ann NY Acad Sci. 1991;615:125-127.
10. Ferrans VJ, Yu ZX, Nelson WK, et al. Lymphangioleiomyomatosis (LAM): a review of clinical and morphological features. J Nippon Med Sch. 2000;67:311-329.
11. Matsumoto Y, Horiba K, Usuki J, et al. Markers of cell proliferation and expression of melanosomal antigen in lymphangioleiomyomatosis. Am J Respir Cell Mol Biol. 1999;21:327-336.
12. Ohori NP, Yousem SA, Sonmez-Alpan E, et al. Estrogen and progesterone receptors in lymphangioleiomyomatosis, epithelioid hemangioendothelioma, and sclerosing hemangioma of the lung. Am J Clin Pathol. 1991;96:529-535.
13. Valencia JC, Matsui K, Bondy C, et al. Distribution and mRNA expression of insulin-like growth factor system in pulmonary lymphangio-leiomyomatosis. J Investig Med. 2001;49:421-433.
14. Matsui K, Beasley MB, Nelson WK, et al. Prognostic significance of pulmonary lymphangioleiomyomatosis histologic score. Am J Surg Pathol. 2001;25:479-484.
15. Smolarek TA, Wessner LL, McCormack FX, et al. Evidence that lymphangiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis. Am J Hum Genet. 1998;62:810-815.
16. Carsillo T, Astrinidis A, Henske EP. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci U S A. 2000;97:6085-6090.
17. Knudson AG. Hereditary cancer: two hits revisited. J Cancer Res Clin Oncol. 1996;122:135-140.
18. Bittmann I, Rolf B, Amann G, et al. Recurrence of lymphangioleiomyomatosis after single lung transplantation: new insights into pathogenesis. Hum Pathol. 2003;34:95-98.
19. Karbowniczek M, Astrinidis A, Balsara BR, et al. Recurrent lymphangioleiomyomatosis after transplantation: genetic analyses reveal a metastatic mechanism. Am J Respir Crit Care Med. 2003;167:976-982. Epub 2002 Oct 31.
20. Crooks DM, Pacheco-Rodriguez G, DeCastro RM, et al. Molecular and genetic analysis of disseminated neoplastic cells in lymphangioleiomyomatosis. Proc Natl Acad Sci U S A. 2004:101:17462-17467. Epub 2004 Dec 6.
21. Henske EP. Metastasis of benign tumor cells in tuberous sclerosis complex. Genes Chromosomes Cancer. 2003;38:376-381.
22. van Slegtenhorst M, de Hoogt R, Hermans C, et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science. 1997;277:805-808.
23. Rosner M, Freilinger A, Hengstschlager M. Proteins interacting with the tuberous sclerosis gene products. Amino Acids. 2004;27:119-128. Epub 2004 Sep 7.
24. Lamb RF, Roy C, Diefenbach TJ, et al. The TSC1 tumour suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho. Nat Cell Biol. 2000;2:281-287.
25. The European Chromosome 16 Tuberous Sclerosis Consortium. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell. 1993;75:1305-1315.
26. Soucek T, Pusch O, Wienecke R, et al. Role of the tuberous sclerosis gene-2 product in cell cycle control. J Biol Chem. 1997;272:29301-29308.
27. Rosner M, Hengstschlager M. Tuberin binds p27 and negatively regulates its interaction with the SCF component Skp2. J Biol Chem. 2004;279:48707-48715. Epub 2004 Sep 8.
28. Soucek T, Rosner M, Miloloza A, et al. Tuberous sclerosis causing mutants of the TSC2 gene product affect proliferation and p27 expression. Oncogene. 2001;20:4904-4909.
29. Inoki K, Li Y, Zhu T, et al. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol. 2002;4:648-657.
30. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell. 2003;115:577-590.
31. Tee AR, Manning BD, Roux PP, et al. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol. 2003;13:1259-1268.
32. Goncharova EA, Goncharova DA, Eszterhas A, et al. Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM). J Biol Chem. 2002;277:30958-30967. Epub 2002 Jun 3.
33. Tee AR, Fingar DC, Manning BD, et al. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci U S A. 2002;99:13571-13576. Epub 2002 Sep 23.
34. Taveira-Dasilva AM, Stylianou MP, Hedin CJ, et al. Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone. Chest. 2004;126:1867-1874.
35. Almoosa KF, Ryu JH, Mendez J, et al. Management of pneumothorax in lymphangioleiomyomatosis: effects on recurrence and lung transplantation complications. Chest. 2006;129:1274-1281.
36. Matsui K, Tatsuguchi A, Valencia J, et al. Extrapulmonary lymphangioleiomyomatosis (LAM): clinicopathologic features in 22 cases. Hum Pathol. 2000;31:1242-1248.
37. Ryu JH, Doerr CH, Fisher SD, et al. Chylothorax in lymphangioleiomyomatosis. Chest. 2003;123:623-627.
38. Avila NA, Kelly JA, Chu SC, et al. Lymphangioleiomyomatosis: abdominopelvic CT and US findings. Radiology. 2000;216:147-153.
39. Jaiswal VR, Baird J, Fleming J, et al. Localized retroperitoneal lymphangioleiomyomatosis mimicking malignancy. A case report and review of the literature. Arch Pathol Lab Med. 2003;127:879-882.
40. Llopis I, Arandiga R, Real E, et al. Lymphangiomyomatosis mimicking an abdominal lymphoma. Haematologica. 2002;87:EIM23.
41. Lu HC, Wang J, Tsang YM, et al. Lymphangioleiomyomatosis initially presenting with abdominal pain: a case report. Clin Imaging. 2003;27:166-170.
42. Wong YY, Yeung TK, Chu WC. Atypical presentation of lymphangioleiomyomatosis as acute abdomen: CT diagnosis. AJR Am J Roentgenol. 2003;181:284-285.
43. Kehagias D, Pafiti A, Vaos N, et al. Retroperitoneal lymphangioleiomyomatosis: CT appearance. Eur Radiol. 1998;8:471-473.
44. Avila NA, Bechtle J, Dwyer AJ, et al. Lymphangioleiomyomatosis: CT of diurnal variation of lymphangioleiomyomas. Radiology. 2001;221:415-421.
45. Bissler JJ, Kingswood JC. Renal angiomyolipomata. Kidney Int. 2004;66:924-934.
46. Moss J, DeCastro R, Patronas NJ, et al. Meningiomas in lymphangioleiomyomatosis. JAMA. 2001;286:1879-1881.
47. Merchant RN, Pearson MG, Rankin RN, et al. Computerized tomography in the diagnosis of lymphangioleiomyomatosis. Am Rev Respir Dis. 1985;131:295-297.
48. Avila NA, Chen CC, Chu SC, et al. Pulmonary lymphangioleiomyomatosis: correlation of ventilation-perfusion scintigraphy, chest radiography, and CT with pulmonary function tests. Radiology. 2000;214:441-446.
49. Avila NA, Kelly JA, Dwyer AJ, et al. Lymphangioleiomyomatosis: correlation of qualitative and quantitative thin-section CT with pulmonary function tests and assessment of dependence on pleurodesis. Radiology. 2002;223:189-197.
50. Avila NA, Dwyer AJ, Murphy-Johnson DV, et al. Sonography of lymphangioleiomyoma in lymphangioleiomyomatosis: demonstration of diurnal variation in lesion size. AJR Am J Roentgenol. 2005;184:459-464.
51. Taveira-DaSilva AM, Hedin C, Stylianou MP, et al. Reversible airflow obstruction, proliferation of abnormal smooth muscle cells, and impairment of gas exchange as predictors of outcome in lymphangioleiomyomatosis. Am J Respir Crit Care Med. 2001;164:1072-1076.
52. Taveira-DaSilva AM, Stylianou MP, Hedin CJ, et al. Maximal oxygen uptake and severity of disease in lymphangioleiomyomatosis. Am J Respir Crit Care Med. 2003;168:1427-1431. Epub 2003 Sep 4.
53. Butnor KJ, Guinee DG Jr. Pleuropulmonary pathology of Birt-Hogg-Dubé syndrome. Am J Surg Pathol. 2006;30:395-399.
54. Painter JN, Tapanainen H, Somer M, et al. A 4-bp deletion in the Birt-Hogg-Dubé gene (FLCN) causes dominantly inherited spontaneous pneumothorax. Am J Hum Genet. 2005;76:522-527. Epub 2005 Jan 18.
55. Tazi A. Adult pulmonary Langerhans' cell histiocytosis. Eur Respir J. 2006;27:1272-1285.
56. Koyama M, Johkoh T, Honda O, et al. Pulmonary involvement in primary Sjögren's syndrome: spectrum of pulmonary abnormalities and computed tomography findings in 60 patients. J Thorac Imaging. 2001;16:290-296.
57. Lohrmann C, Uhl M, Warnatz K, et al. High-resolution CT imaging of the lung for patients with primary Sjögren's syndrome. Eur J Radiol. 2004;52:137-143.
58. Johnson SR, Whale CI, Hubbard RB, et al. Survival and disease progression in UK patients with lymphangioleiomyomatosis. Thorax. 2004;59:800-803.
59. Johnson SR, Tattersfield AE. Decline in lung function in lymphangioleiomyomatosis: relation to menopause and progesterone treatment. Am J Respir Crit Care Med. 1999;160:628-633.
60. Burrows B, Lebowitz MD, Camilli AE, et al. Longitudinal changes in forced expiratory volume in one second in adults: methodologic considerations and findings in healthy nonsmokers. Am Rev Respir Dis. 1986;133:974-980.
61. Sherrill DL, Enright PL, Kaltenborn WT, et al. Predictors of longitudinal change in diffusing capacity over 8 years. Am J Respir Crit Care Med. 1999;160:1883-1887.
62. Dowson LJ, Guest PJ, Stockley RA. Longitudinal changes in physiological, radiological, and health status measurements in alpha(1)-antitrypsin deficiency and factors associated with decline. Am J Respir Crit Care Med. 2001;164(10 Pt 1):1805-1809.
63. Brunelli A, Catalini G, Fianchini A. Pregnancy exacerbating unsuspected mediastinal lymphangioleiomyomatosis and chylothorax. Int J Gynaecol Obstet. 1996;52:289-290.
64. Yano S. Exacerbation of pulmonary lymphangioleiomyomatosis by exogenous oestrogen used for infertility treatment. Thorax. 2002;57:1085-1086.
65. Eliasson AH, Phillips YY, Tenholder MF. Treatment of lymphangioleiomyomatosis: a meta-analysis. Chest. 1989;96:1352-1355.
66. Taylor JR, Ryu J, Colby TV, et al. Lymphangioleiomyomatosis: clinical course in 32 patients. N Engl J Med. 1990;323:1254-1260.
67. Rossi GA, Balbi B, Oddera S, et al. Response to treatment with an analog of luteinizing-hormone-releasing hormone in a patient with pulmonary lymphangioleiomyomatosis. Am Rev Respir Dis. 1991;143:174-176.
68. Medeiros P Jr, Kairalla RA, Pereira CAC, et al. GnRH analogs X progesterone-lung function evolution in two treatment cohort groups in lymphangioleiomyomatosis (LAM). Am J Respir Crit Care Med. 2003;167:A953.
69. de la Fuente J, Parámo C, Román F, et al. Lymphangioleiomyomatosis: unsuccessful treatment with luteinizing-hormone- releasing hormone analogues. Eur J Med. 1993;2:377-378.
70. Zahner J, Borchard F, Fischer H, et al. Successful therapy of a post-partum lymphangioleiomyomatosis. Case report and literature review [in German]. Schweiz Med Wochenschr. 1994;124:1626-1632.
71. Ryu JH, Doerr CH, Fisher SD, et al. Chylothorax in lymphangioleiomyomatosis. Chest. 2003;123:623-627.
72. Almoosa KF, McCormack FX, Sahn SA. Pleural disease in lymphangioleiomyomatosis. Clin Chest Med. 2006;27:355-368.
73. Druelle S, Aubry P, Levi-Valensi P. Pulmonary lymphangiomyomatosis: a 3-year follow-up of medroxyprogesterone acetate therapy. Apropos of a case [in French]. Rev Pneumol Clin. 1995;51:284-287.
74. Boudard C, Gamondes JP, Mornex JF, et al. Pleuro-peritoneal Denver shunt in treatment of chronic pleurisy [in French]. Ann Chir. 1998;52:192-196.
75. Wojcik P, Otto TJ, Jagiello R, et al. Use of pleuro-peritoneal shunt in the treatment of chronic chylothorax [in Polish]. Pneumonol Alergol Pol. 1998;66:473-479.
76. Lam B, Ooi GC, Wong MP, et al. Extrapulmonary presentation of asymptomatic pulmonary lymphangioleiomyomatosis. Respirology. 2003;8:544-547.
77. Kimura M, Morikawa T, Takeuchi K, et al. Lymphangioleiomyomatosis with chylous ascites treatment successfully by peritoneo-venous shunting [in Japanese]. Nihon Kyobu Shikkan Gakkai Zasshi. 1996;34:557-562.
78. Widjaja A, Gratz KF, Ockenga J, et al. Octreotide for therapy of chylous ascites in yellow nail syndrome. Gastroenterology. 1999;116:1017-1018.
79. Makrilakis K, Pavlatos S, Giannikopoulos G, et al. Successful octreotide treatment of chylous pleural effusion and lymphedema in the yellow nail syndrome. Ann Intern Med. 2004;141:246-247.
80. Pechet TT, Meyers BF, Guthrie TJ, et al. Lung transplantation for lymphangioleiomyomatosis. J Heart Lung Transplant. 2004;23:301-308.
81. Kpodonu J, Massad MG, Chaer RA, et al. The US experience with lung transplantation for pulmonary lymphangioleiomyomatosis. J Heart Lung Transplant. 2005;24:1247-1253.
82. Hsu TH, O'Hara J, Mehta A, Levitin A, et al. Nephron-sparing nephrectomy for giant renal angiomyolipoma associated with lymphangioleiomyomatosis. Urology. 2002;59:138.
83. Kenerson H, Dundon TA, Yeung RS. Effects of rapamycin in the Eker rat model of tuberous sclerosis complex. Pediatr Res. 2005;57:67-75. Epub 2004 Nov 19.
84. Yeung RS. Multiple roles of the tuberous sclerosis complex genes. Genes Chromosomes Cancer. 2003;38:368-375.
85. Shapiro SD. Chairman's summary. Proc Am Thorac Soc. 2006;3:397-400.
86. Ji RC. Lymphatic endothelial cells, lymphangiogenesis, and extracellular matrix. Lymphat Res Biol. 2006;4:83-100.
87. Hayashi T, Fleming MV, Stetler-Stevenson WG, et al. Immunohistochemical study of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in pulmonary lymphangioleiomyomatosis (LAM). Hum Pathol. 1997;28:1071-1078.
88. Matsui K, Takeda K, Yu ZX, et al. Role for activation of matrix metalloproteinases in the pathogenesis of pulmonary lymphangioleiomyomatosis. Arch Pathol Lab Med. 2000;124:267-275.
89. Krymskaya VP, Shipley JM. Lymphangioleiomyomatosis: a complex tale of serum response factor-mediated tissue inhibitor of metalloproteinase-3 regulation. Am J Respir Cell Mol Biol. 2003;28:546-550.
90. Zhe X, Yang Y, Jakkaraju S, et al. Tissue inhibitor of metalloproteinase-3 downregulation in lymphangioleiomyomatosis: potential consequence of abnormal serum response factor expression. Am J Respir Cell Mol Biol. 2003;28:504-511.
91. Moses MA, Wiederschain D, Loughlin KR, et al. Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res. 1998;58:1395-1399.
92. Roy R, Wewer UM, Zurakowski D, et al. ADAM 12 cleaves extracellular matrix proteins and correlates with cancer status and stage. J Biol Chem. 2004;279:51323-51330. Epub 2004 Sep 20.
93. Marler JJ, Fishman SJ, Kilroy SM, et al. Increased expression of matrix metalloproteinases parallels the extent and activity of vascular anomalies. Pediatrics. 2005;116:38-45.
94. Fernandez CA, Yan L, Louis G, et al. The matrix metalloproteinase-9/ neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients. Clin Cancer Res. 2005;11:5390-5395.
95. Ginns LC, Roberts DH, Mark EJ, et al. Pulmonary capillary hemangiomatosis with atypical endotheliomatosis: successful antiangiogenic therapy with doxycycline. Chest. 2003;124:2017-2022.
96. Saikali Z, Singh G. Doxycycline and other tetracyclines in the treatment of bone metastasis. Anticancer Drugs. 2003;14:773-778.
97. Gilbertson-Beadling S, Powers EA, Stamp-Cole M, et al. The tetracycline analogs minocycline and doxycycline inhibit angiogenesis in vitro by a non-metalloproteinase-dependent mechanism. Cancer Chemother Pharmacol. 1995;36:418-424.
98. Richardson M, Wong D, Lacroix S, et al. Inhibition by doxycycline of angiogenesis in the chicken chorioallantoic membrane (CAM). Cancer Chemother Pharmacol. 2005;56:1-9.
99. Onoda T, Ono T, Dhar DK, et al. Tetracycline analogues (doxycycline and COL-3) induce caspase-dependent and -independent apoptosis in human colon cancer cells. Int J Cancer. 2005;118:1309-1315.
100. Duivenvoorden WCM, Popovic SV, Lhoták S, et al. Doxycycline decreases tumor burden in a bone metastasis model of human breast cancer. Cancer Res. 2002;62:1588-1591.
101. Chhipa RR, Singh S, Surve SV, et al. Doxycycline potentiates antitumor effect of cyclophosphamide in mice. Toxicol Appl Pharmacol. 2005;202:268-277.
102. Franco C, Ho B, Mulholland D, et al. Doxycycline alters vascular smooth muscle cell adhesion, migration, and reorganization of fibrillar collagen matrices. Am J Pathol. 2006;168:1697-1709.
103. Folkman J. Angiogenesis inhibitors: a new class of drugs. Cancer Biol Ther. 2003;2:(4 suppl 1):S127-S133.
104. Chang L, Kaipainen A, Folkman J. Lymphangiogenesis new mechanisms. Ann N Y Acad Sci. 2002;979:111-119.
105. Moses MA, Harper J, Folkman J. Doxycycline treatment for lymphangioleiomyomatosis with urinary monitoring for MMPs. N Engl J Med. 2006;354:2621-2622.